Dr Alan MacDonald


Dr Alan MacDonald has been a member of Scottish Medicines Consortium (SMC) since 2007, and joined SMC Executive in 2013 as Vice Chair of SMC’s technical appraisal committee, New Drugs Committee (NDC). He was Chair of NDC from 2014 until 2017 and was appointed Chair of SMC in April 2017.

A medical graduate of the University of Glasgow, he trained in General Medicine and Rheumatology before being appointed as Consultant Rheumatologist at Aberdeen Royal Infirmary in 1996, where he continues to practice. He is a past President of the Scottish Society for Rheumatology (SSR)

Session title

Ensuring access to new medicines across Scotland

Session synopsis

In 2016, the Review of Access to New Medicines was published and laid out a range of recommendations for increasing the access patients in Scotland had to new medicines. The Scottish Medicines Consortium and Scottish Government have led significant progress in increasing access to medicine, however, our evolving understanding of cancer as a disease is leading to newer, more personalised treatments such as precision medicines and immunotherapies, but also adding complexity and cost. This session will ask what more can be done to allow as many patients in Scotland to access new medicines whilst maintaining cost-effectiveness of this access for NHS Scotland.